淋巴清除后的反应影响接受CD19 CAR T细胞治疗的侵袭性非霍奇金淋巴瘤患者的无进展生存期
该研究对接受环磷酰胺联合氟达拉滨淋巴清除后输注2×10^6/kg CD19 CAR T细胞的侵袭性B细胞非霍奇金淋巴瘤患者进行多变量分析,最佳总缓解率为51%,完全缓解率为40%,完全缓解患者的中位无进展生存期为20.0个月(中位随访26.9个月)。淋巴清除前较低的血清乳酸脱氢酶水平和有利的细胞因子谱(第0天血清MCP-1和峰值IL-7浓度高于中位数)与更好的无进展生存期相关。
要点
- 最佳总缓解率51%,完全缓解率40%,完全缓解患者中位PFS 20.0个月。
- 淋巴清除前低LDH及有利细胞因子谱与更好PFS相关。
- 高强度的环磷酰胺联合氟达拉滨淋巴清除与有利细胞因子谱概率更高相关。
核心结论
- 淋巴清除前较低的血清LDH水平和有利的细胞因子谱与接受CD19 CAR T细胞治疗的侵袭性NHL患者更好的PFS相关。
研究设计与样本
- 对接受环磷酰胺和氟达拉滨淋巴清除后输注2×10^6 CD19 CAR T细胞/kg的侵袭性NHL患者进行多变量分析,临床试验注册号NCT01865617。
主要发现
- 最佳总缓解率为51%,40%的患者达到完全缓解。
- 达到完全缓解的侵袭性NHL患者中位PFS为20.0个月(中位随访26.9个月)。
- 淋巴清除后MCP-1和IL-7浓度升高,且更高强度的环磷酰胺和氟达拉滨淋巴清除与有利细胞因子谱概率更高相关。
- 接受高强度淋巴清除且获得有利细胞因子谱的患者PFS优于接受相同强度淋巴清除但未获得有利细胞因子谱的患者。
- 即使在淋巴清除前血清LDH高于正常的的高危患者中,淋巴清除后有利细胞因子谱也与低PFS事件风险相关。
关键数值与推荐
- 有利细胞因子谱定义为第0天血清MCP-1和峰值IL-7浓度高于中位数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting response and progression-free survival (PFS) in patients with aggressive NHL treated with cyclophosphamide and fludarabine lymphodepletion followed by 2 × 106 CD19-directed CAR T cells/kg. The best overall response rate was 51%, with 40% of patients achieving complete remission. The median PFS of patients with aggressive NHL who achieved complete remission was 20.0 months (median follow-up, 26.9 months). Multivariable analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS. MCP-1 and IL-7 concentrations increased after lymphodepletion, and higher intensity of cyclophosphamide and fludarabine lymphodepletion was associated with higher probability of a favorable cytokine profile. PFS was superior in patients who received high-intensity lymphodepletion and achieved a favorable cytokine profile compared with those who received the same intensity of lymphodepletion without achieving a favorable cytokine profile. Even in high-risk patients with pre-lymphodepletion serum LDH levels above normal, a favorable cytokine profile after lymphodepletion was associated with a low risk of a PFS event. Strategies to augment the cytokine response to lymphodepletion could be tested in future studies of CD19 CAR T-cell immunotherapy for aggressive B-cell NHL. This trial was registered at www.clinicaltrials.gov as #NCT01865617.
引用
- Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019. PMID: 30782611. doi:10.1182/blood-2018-11-887067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。